Guess Who Picked Onconova Therapeutics Inc. (NASDAQ:ONTX) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Onconova Therapeutics Inc. (NASDAQ:ONTX) reported that Sabby Capital has picked up 702,896 of common stock as of 2017-05-01.

The acquisition brings the aggregate amount owned by Sabby Capital to a total of 702,896 representing less than 7.61% stake in the company.

For those not familiar with the company, Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

A glance at Onconova Therapeutics Inc. (NASDAQ:ONTX) key stats reveals a current market capitalization of 22.72 Million based on 9.24 Million shares outstanding and a price at last close of $2.35 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-26, Bienen picked up 3,810 at a purchase price of $2.10. This brings their total holding to 12,724 as of the date of the filing.

On the sell side, the most recent transaction saw Kumar unload 20,000 shares at a sale price of 15.11. This brings their total holding to 276,500.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Onconova Therapeutics Inc. (NASDAQ:ONTX) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Arena Pharmaceuticals Inc (NASDAQ:ARNA) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Arena Pharmaceuticals Inc (NASDAQ:ARNA) reported that Great Point Partners has picked up 30,000,000 of common stock as of 2017-04-28.

The acquisition brings the aggregate amount owned by Great Point Partners to a total of 30,000,000 representing less than 9.75% stake in the company.

For those not familiar with the company, Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company’s programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

A glance at Arena Pharmaceuticals Inc (NASDAQ:ARNA)’s key stats reveals a current market capitalization of 409.39 Million based on 307.73 Million shares outstanding and a price at last close of $1.34 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-26, Munshi picked up 50,000 at a purchase price of $1.41. This brings their total holding to 51,875 as of the date of the filing.

On the sell side, the most recent transaction saw White unload 18,728 shares at a sale price of $1.99. This brings their total holding to 85,529.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Arena Pharmaceuticals Inc (NASDAQ:ARNA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

Here is Who Just Picked Ptc Therapeutics Inc. (NASDAQ:PTCT)

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ptc Therapeutics Inc. (NASDAQ:PTCT) reported that Complete Pharma Holdings Ii, Llc. has picked up 6,683,598 of common stock as of 2017-04-27.

The acquisition brings the aggregate amount owned by Complete Pharma Holdings Ii, Llc. to a total of 6,683,598 representing less than 16.2% stake in the company.

For those not familiar with the company, PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

A glance at Ptc Therapeutics Inc. (NASDAQ:PTCT)’s key stats reveals a current market capitalization of 420.63 Million based on 34.56 Million shares outstanding and a price at last close of $12.01 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-03, Rothera picked up 2,000 at a purchase price of $6.23. This brings their total holding to 5,125 as of the date of the filing.

On the sell side, the most recent transaction saw Almstead unload 78 shares at a sale price of $11.82. This brings their total holding to 2,687.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ptc Therapeutics Inc. (NASDAQ:PTCT) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Oncomed Pharmaceuticals Inc (NASDAQ:OMED) reported that Biotechnology Value Fund L P has picked up 1,372,923 of common stock as of 2017-04-27.

The acquisition brings the aggregate amount owned byBiotechnology Value Fund L P to a total of 1,372,923 representing less than 3.6% stake in the company.

For those not familiar with the company, OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

A glance at Oncomed Pharmaceuticals Inc (NASDAQ:OMED)’s key stats reveals a current market capitalization of 160.50 Million based on 37.62 Million shares outstanding and a price at last close of $4.00 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-09-30, Lasersohn picked up 9,120 at a purchase price of $16.26. This brings their total holding to 46,560 as of the date of the filing.

On the sell side, the most recent transaction saw Lewicki unload 5,711 shares at a sale price of $9.06. This brings their total holding to 22,937.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Oncomed Pharmaceuticals Inc (NASDAQ:OMED) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Rtw Investments is Buying Ptc Therapeutics Inc. (NASDAQ:PTCT) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ptc Therapeutics Inc. (NASDAQ:PTCT) reported that Rtw Investments, Lp. has picked up 1,794,336 of common stock as of 2017-04-21.

The acquisition brings the aggregate amount owned by Rtw Investments, Lp. to a total of 1,794,336 representing less than 5.2% stake in the company.

For those not familiar with the company, PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

A glance at Ptc Therapeutics Inc. (NASDAQ:PTCT)’s key stats reveals a current market capitalization of 392.91 Million based on 34.56 Million shares outstanding and a price at last close of $11.37 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-03 Rothera picked up 2,000 at a purchase price of $6.23. This brings their total holding to 5,125 as of the date of the filing.

On the sell side, the most recent transaction saw Almstead unload 78 shares at a sale price of $11.82. This brings their total holding to 2,687.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ptc Therapeutics Inc. (NASDAQ:PTCT) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Flynn James E Picked Mannkind Corp (NASDAQ:MNKD) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mannkind Corp (NASDAQ:MNKD) reported that Flynn James E has picked up 5,217,391 of common stock as of 2017-04-19.

The acquisition brings the aggregate amount owned by Flynn James E to a total of 5,217,391 representing a 5.17% stake in the company.

For those not familiar with the company, MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

A glance at Mannkind Corp (NASDAQ:MNKD)’s key stats reveals a current market capitalization of 113.14 Million based on 95.78 Million shares outstanding and a price at last close of $1.22 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-01-03, Pfeffer picked up 4,540 at a purchase price of $0.54. This brings their total holding to 403,085 as of the date of the filing.

On the sell side, the most recent transaction saw Alinaya unload 6,294 shares at a sale price of $1.06. This brings their total holding to 131,413.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Mannkind Corp (NASDAQ:MNKD) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Kadmon Holdings Inc. (NYSE:KDMN) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kadmon Holdings Inc. (NYSE:KDMN) reported that Perceptive Advisors has picked up 5,185,847 of common stock as of 2017-03-17.

The acquisition brings the aggregate amount owned by Perceptive Advisors to a total of 5,185,847 representing a 10.00% stake in the company.

For those not familiar with the company, Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

A glance at Kadmon Holdings Inc. (NYSE:KDMN)’s key stats reveals a current market capitalization of 159.08 Million based on 45.08 Million shares outstanding and a price at last close of $3.57 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-13, Loeb picked up 1,488,095 at a purchase price of $3.36. This brings their total holding to 9,407,745 as of the date of the filing.

On the sell side, the most recent transaction saw Marquardt unload 5,852 shares at a sale price of $49.06. This brings their total holding to 76,184.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kadmon Holdings Inc. (NYSE:KDMN) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

 

Skip to content